GlassScriptPhysician profile
Gerald P Falkenstein
NPI 1790748978
$3,691.46
in general payments reported to CMS, 2019-2025
26 companies · $22.10 in 2025
The $22.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $616 · 2021: $470 · 2022: $391 · 2023: $573 · 2024: $333 · 2025: $22.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $714.46 | 2021-2025 | |
| Novo Nordisk INC | $669.11 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $400.27 | 2019-2023 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $296.61 | 2019-2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.70 | 2019-2021 | |
| Allergan, INC. | $178.89 | 2019-2020 | |
| Amgen INC. | $177.63 | 2019-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $174.64 | 2019-2021 | |
| Amarin Pharma, INC. | $159.07 | 2019-2021 | |
| Glaxosmithkline, LLC. | $158.98 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $102.71 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $71.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.89 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $56.05 | 2019 | |
| Esperion Therapeutics, INC. | $46.06 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.31 | 2019-2020 | |
| Astellas Pharma US INC | $42.57 | 2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $23.44 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.17 | 2020 | |
| Phathom Pharmaceuticals, INC. | $19.69 | 2023 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.30 | 2019 | |
| Abbott Laboratories | $15.60 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $13.54 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $12.19 | 2021 | |
| Genentech USA, INC. | $11.95 | 2020 | |
| Eisai INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Falkenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.